These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 14532138)
41. RA treatment study group: improvement in RA management. Ward M; Liang MH; Burns T; Singh G Joint Bone Spine; 2009 Jul; 76(4):435-7. PubMed ID: 19541527 [No Abstract] [Full Text] [Related]
43. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L Ann Rheum Dis; 2005 Oct; 64(10):1421-6. PubMed ID: 15829572 [TBL] [Abstract][Full Text] [Related]
44. Infectious complications of biologic agents. Martin-Mola E; Balsa A Rheum Dis Clin North Am; 2009 Feb; 35(1):183-99. PubMed ID: 19481004 [TBL] [Abstract][Full Text] [Related]
45. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP; Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999 [TBL] [Abstract][Full Text] [Related]
46. Safety and efficacy of the biologic response modifiers. Markenson J Am J Orthop (Belle Mead NJ); 2007 Mar; 36(3 Suppl):15-9. PubMed ID: 17491583 [No Abstract] [Full Text] [Related]
47. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Bongartz T; Sutton AJ; Sweeting MJ; Buchan I; Matteson EL; Montori V JAMA; 2006 May; 295(19):2275-85. PubMed ID: 16705109 [TBL] [Abstract][Full Text] [Related]
48. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis. Cohen SB Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046 [TBL] [Abstract][Full Text] [Related]
49. New therapies for rheumatoid arthritis. Goldblatt F; Isenberg DA Clin Exp Immunol; 2005 May; 140(2):195-204. PubMed ID: 15807842 [TBL] [Abstract][Full Text] [Related]
58. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis? Gabriel SE Arthritis Rheum; 2008 Mar; 58(3):637-40. PubMed ID: 18311805 [No Abstract] [Full Text] [Related]
59. Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Talwalkar SC; Grennan DM; Gray J; Johnson P; Hayton MJ Ann Rheum Dis; 2005 Apr; 64(4):650-1. PubMed ID: 15769927 [No Abstract] [Full Text] [Related]
60. Which TNF inhibitor for rheumatoid arthritis? Med Lett Drugs Ther; 2010 May; 52(1338):38-9. PubMed ID: 20467356 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]